Daewoong Pharma
KRX:069620
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
99 900
150 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Daewoong Pharma
Daewoong Pharma
Total Current Liabilities
Daewoong Pharma
Total Current Liabilities Peer Comparison
000100
326030
128940
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Daewoong Pharma
KRX:069620
|
Total Current Liabilities
₩667.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
20%
|
CAGR 10-Years
24%
|
|
|
Yuhan Corp
KRX:000100
|
Total Current Liabilities
₩648.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Total Current Liabilities
₩241.6B
|
CAGR 3-Years
51%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Total Current Liabilities
₩678.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
15%
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Total Current Liabilities
₩74.2B
|
CAGR 3-Years
32%
|
CAGR 5-Years
14%
|
CAGR 10-Years
12%
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Total Current Liabilities
₩248.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
See Also
What is Daewoong Pharma's Total Current Liabilities?
Total Current Liabilities
667.1B
KRW
Based on the financial report for Jun 30, 2024, Daewoong Pharma's Total Current Liabilities amounts to 667.1B KRW.
What is Daewoong Pharma's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
24%
Over the last year, the Total Current Liabilities growth was 26%. The average annual Total Current Liabilities growth rates for Daewoong Pharma have been 14% over the past three years , 20% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
